Method for Selecting Patient Subpopulation for Custirsen Treatment

摘要

A method of determining if a cancer patient is susceptible to survival prolongation if treatment is augmented with a clusterin-inhibiting pharmaceutical is provided. The method involves measurement of various patient data and a systematic approach to the analysis. A computer-aided system is also provided.

主权项

1. A method for determining if a prostate cancer-afflicted patient is susceptible to survival prolongation through treatment with a clusterin-inhibiting agent in combination with a chemotherapy agent, the method comprising the steps of:
(a) obtaining a plurality of test results for a patient, said test results being selected from the group consisting of:
(i) a Performance Scale result,(ii) the presence of metastatic lesions on the patient's liver,(iii) blood prostate specific antigen (PSA) level,(iv) blood lactose dehydrogenase (LDH) level, and(v) hemoglobin (Hb) levels; (b) comparing each of the obtained test results to a predetermined value for the test result indicative of a poor prognosis; and (c) if any two of the resulting five measurements indicate poor prognosis in a cancer patient concluding that said patient is susceptible to survival prolongation through treatment with a clusterin-inhibiting agent in combination with a chemotherapy agent.